This database contains 1063 studies, archived under the term: "female"
Click here to filter this large number of results.
Passive movement therapy in severe paratonia: a multicenter randomized clinical trial
Background: Paratonia causes severe movement dysfunction in late stage dementia. Passive Movement Therapy (PMT) is often used to decrease high muscle tone, but the efficacy has never been shown. The objective of this study is to investigate the effect of PMT on muscle tone after two and four weeks of treatment.; Methods: This study comprised […]
Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg
Herrschaft, Horst,
Nacu, Anatol,
Likhachev, Sergey,
Sholomov, Ilya,
Hoerr, Robert,
Schlaefke, Sandra
A multi-centre, double-blind, randomised, placebo-controlled, 24-week trial with 410 outpatients was conducted to demonstrate efficacy and safety of a 240 mg once-daily formulation of Ginkgo biloba extract EGb 761(®) in patients with mild to moderate dementia (Alzheimer’s disease or vascular dementia) associated with neuropsychiatric symptoms. Patients scored 9 to 23 on the SKT cognitive battery, […]
Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson’s disease
Witt, Karsten,
Daniels, Christine,
Krack, Paul,
Volkmann, Jens,
Pinsker, Markus O.,
Kloss, Manja,
Tronnier, Volker,
Schnitzler, Alfons,
Wojtecki, Lars,
Bötzel, Kai,
Danek, Adrian,
Hilker, Rüdiger,
Sturm, Volker,
Kupsch, Andreas,
Karner, Elfriede,
Deuschl, Günther
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) significantly improves quality of life (QoL) in Parkinson’s disease (PD). Dementia is considered as a contraindication for STN-DBS. However, no controlled study assessed the impact of STN-DBS on the QoL and motor outcome in PD patients with a borderline global cognitive impairment. We studied clinical baseline […]
A randomized feasibility study of a 12-week community-based exercise program for people with Huntington’s disease
Busse, Monica,
Quinn, Lori,
Debono, Katy,
Jones, Karen,
Collett, Johnathan,
Playle, Rebecca,
Kelly, Mark,
Simpson, Sharon,
Backx, Karianne,
Wasley, David,
Dawes, Helen,
Rosser, Anne
BACKGROUND AND PURPOSE: The beneficial role of exercise as a treatment approach in Huntington’s disease (HD) has support from both preclinical work and small-scale studies; however, there have been no controlled studies of gym-based exercise in people with HD. This phase 2 randomized trial (ISRCTN 59910670) assessed feasibility, safety, acceptability, and benefit of a structured […]
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer’s disease
Cummings, Jeffrey,
Froelich, Lutz,
Black, Sandra E.,
Bakchine, Serge,
Bellelli, Giuseppe,
Molinuevo, José L.,
Kressig, Reto W.,
Downs, Pamela,
Caputo, Angelika,
Strohmaier, Christine
Aim: Determine whether patients with Alzheimer’s disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses.; Methods: Patients meeting prespecified decline criteria were randomized to receive 9.5 or 13.3 mg/24 […]
Donepezil and memantine for moderate-to-severe Alzheimer’s disease
Howard, Robert,
McShane, Rupert,
Lindesay, James,
Ritchie, Craig,
Baldwin, Ashley,
Barber, Robert,
Burns, Alistair,
Dening, Tom,
Findlay, David,
Holmes, Clive,
Hughes, Alan,
Jacoby, Robin,
Jones, Rob,
Jones, Roy,
McKeith, Ian,
Macharouthu, Ajay,
O'Brien, John,
Passmore, Peter,
Sheehan, Bart,
Juszczak, Edmund,
Katona, Cornelius,
Hills, Robert,
Knapp, Martin,
Ballard, Clive,
Brown, Richard,
Banerjee, Sube,
Onions, Caroline,
Griffin, Mary,
Adams, Jessica,
Gray, Richard,
Johnson, Tony,
Bentham, Peter,
Phillips, Patrick
Background: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.; Methods: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer’s […]
Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
Hanney, Marisa,
Prasher, Vee,
Williams, Nicola,
Jones, Emma L.,
Aarsland, Dag,
Corbett, Anne,
Lawrence, Dale,
Yu, Ly-Mee,
Tyrer, Stephen,
Francis, Paul T.,
Johnson, Tony,
Bullock, Roger,
Ballard, Clive
Background: Prevalence of Alzheimer’s disease in people with Down’s syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer’s disease. Evidence to support treatment with Alzheimer’s drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine […]
Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial
Fox, Chris,
Crugel, Monica,
Maidment, Ian,
Auestad, Bjorn Henrik,
Coulton, Simon,
Treloar, Adrian,
Ballard, Clive,
Boustani, Malaz,
Katona, Cornelius,
Livingston, Gill
Background: Agitation in Alzheimer’s disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary […]